文献速递肾小球疾病慢性肾脏病

APOL1高危变异G1与G2介导的肾病对ACE抑制敏感性不同

Differing sensitivities to angiotensin converting enzyme inhibition of kidney disease mediated by APOL1 high-risk variants G1 and G2.
PubMed 文献 · Kidney Int · 2024-08-23

在APOL1 BAC转基因小鼠模型中,标准剂量赖诺普利使G1/G1小鼠蛋白尿降低约90倍并减轻肾小球硬化,且不依赖血压;G2/G2小鼠需双倍剂量才获较小获益,达格列净对两者均无效。

要点

  • 标准剂量赖诺普利对APOL1 G1/G1小鼠降蛋白尿和抗肾小球硬化效果显著。
  • G2/G2小鼠需双倍剂量赖诺普利才获较小获益,提示反应性差异。
  • 达格列净在G1/G1和G2/G2小鼠中均未改变疾病进展。

核心结论

  • 在此APOL1肾病小鼠模型中,标准剂量赖诺普利的降蛋白尿和抗肾小球硬化作用在G1/G1中显著优于G2/G2。

研究设计与样本

  • 在APOL1 BAC转基因小鼠注射pCpG-free IFN-γ质粒诱导蛋白尿后,将G1/G1和G2/G2蛋白尿小鼠随机分为药物治疗组或不治疗组。
  • 赖诺普利、达格列净和肼屈嗪自第7天起经饮水给药。
  • 每周测尿白蛋白/肌酐比两次,肾脏行组织学检查并以PAS染色切片计算局灶节段性肾小球硬化评分。

主要发现

  • 标准剂量赖诺普利使APOL1 G1/G1 BAC转基因小鼠蛋白尿降低约90倍并减轻肾小球硬化,且不依赖血压。
  • 达格列净在G1/G1或G2/G2小鼠中均未改变疾病进展。
  • G2/G2小鼠需赖诺普利剂量为G1/G1有效剂量的两倍才实现蛋白尿减少和肾小球硬化减轻,但获益小得多。
  • 肼屈嗪达到相当降压效果但未提供类似保护。

关键数值与推荐

  • 标准剂量赖诺普利:G1/G1小鼠蛋白尿降低约90倍。
  • G2/G2小鼠:赖诺普利剂量需为G1/G1有效剂量的两倍。

临床怎么用

  • 提示APOL1高危变异携带者肾病的ACE抑制剂反应可能存在基因型差异,但需在患者中验证。

局限性

  • 研究为APOL1 BAC转基因小鼠模型,ACE抑制剂反应差异是否见于患者尚待确定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Apolipoprotein L1 (APOL1) variants G1 and G2 contribute to the excess risk of kidney disease in individuals of recent African ancestry. Since disease mechanisms and optimal treatments remain controversial, we study the effect of current standard-of-care drugs in mouse models of APOL1 kidney disease. Experiments were performed in APOL1 BAC-transgenic mice, which develop proteinuria and glomerulosclerosis following injection with a pCpG-free IFN-γ plasmid. Proteinuric, plasmid injected G1/G1 and G2/G2 mice were randomized to drug treatment or no treatment. Lisinopril, dapagliflozin, and hydralazine were administered in drinking water starting day seven. The urine albumin/creatinine ratio was measured twice weekly, and the kidneys examined histologically with the focal segmental glomerulosclerosis score computed from periodic acid-Shiff-stained sections. The angiotensin converting enzyme inhibitor lisinopril, at standard dose, reduced proteinuria by approximately 90-fold and reduced glomerulosclerosis in the APOL1 G1/G1 BAC-transgenic mice. These effects were independent of blood pressure. Dapagliflozin did not alter disease progression in either G1/G1 or G2/G2 mice. Proteinuria reduction and glomerulosclerosis in G2/G2 BAC-transgenic mice required lisinopril doses two times higher than were effective in G1/G1 mice but achieved a much smaller benefit. Therefore, in these BAC-transgenic mouse models of APOL1 disease, the anti-proteinuric and anti-glomerulosclerotic effects of standard dose lisinopril were markedly effective in G1/G1 compared with G2/G2 APOL1 mice. Comparable reduction in blood pressure by hydralazine treatment provided no such protection. Neither G1/G1 nor G2/G2 mice showed improvement with the sodium-glucose cotransporter-2 inhibition dapagliflozin. Thus, it remains to be determined if similar differences in ACE inhibitor responsiveness are observed in patients.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Sula Karreci E, Jacas S, Donovan O, et al. Differing sensitivities to angiotensin converting enzyme inhibition of kidney disease mediated by APOL1 high-risk variants G1 and G2. Kidney Int. 2024. PMID: 39181397. doi:10.1016/j.kint.2024.07.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。